Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-18T17:37:22.606Z Has data issue: false hasContentIssue false
  • English
  • Français

Function of the nucleus of the solitary tract in the therapeutic effect of obesity medication lorcaserin

Published online by Cambridge University Press:  08 February 2022

S. Wagner ,
D.I. Brierley ,
A. Leeson-Payne ,
R. Chianese ,
S. Trapp  and
L.K. Heisler
S. Wagner
Affiliation:
The Rowett Institute, University of Aberdeen, Aberdeen, UK
D.I. Brierley
Affiliation:
Centre for Cardiovascular and Metabolic Neuroscience, University College London, London, UK
A. Leeson-Payne
Affiliation:
The Rowett Institute, University of Aberdeen, Aberdeen, UK
R. Chianese
Affiliation:
The Rowett Institute, University of Aberdeen, Aberdeen, UK
S. Trapp
Affiliation:
Centre for Cardiovascular and Metabolic Neuroscience, University College London, London, UK
L.K. Heisler
Affiliation:
The Rowett Institute, University of Aberdeen, Aberdeen, UK
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Abstract
Information
Proceedings of the Nutrition Society , Volume 81 , Issue OCE1: Winter Conference 2021, 7–8 December 2021, Obesity and the brain , 2022 , E50
Check for updates
Copyright
Copyright © The Authors 2022

Obesity and overweight are leading healthcare issues in developed countries. Despite considerable clinical demand, limited pharmaceutical treatment options are currently available. Amongst those recently developed are the serotonin 2C receptor (5-HT2CR) agonist lorcaserin, glucagon-like peptide-1 receptor (GLP-1R) agonists (e.g. liraglutide) and melanocortin-4 (MC4R) agonists (e.g. setmelanotide). Defining whether these medications target the same or parallel brain circuits to improve obesity is the objective of the present work. 5-HT2CRs, GLP-1Rs, and MC4Rs are distributed throughout the brain including in the key homeostatic region of the nucleus of the solitary tract (NTS)(Reference D'Agostino, Lyons and Cristiano1,Reference Alhadeff, Mergler and Zimmer2) . The NTS has a major role in the regulation of food intake and several neuropeptides, including GLP-1 produced by preproglucagon (PPGNTS) neurons, are localized here(Reference Holt, Richards and Cook3).

Adult male and female mice were used to investigate the therapeutic mechanism of obesity medications lorcaserin. To examine the potential interaction between the serotonin and GLP-1 circuits, neurons within the NTS making GLP-1 were ablated (PPGNTS ablation) or GLP-1 receptors were specifically knocked down within the NTS (GLP-1RNTS knockdown). All studies were conducted in accordance with The Animals (Scientific Procedures) Act 1986 and the principles of the 3Rs.

Our results demonstrate that 5-HT2CR agonist lorcaserin requires functional PPGNTS neurons to reduce food intake in mice. Lorcaserin significantly reduced cumulative 1–4 hour food intake in control mice but not PPGNTS ablated mice (F(1,26) = 9.977, p = 0.004). Further analysis of the underlying neurocircuitry shows that approximately one-third of PPGNTS neurons express 5-HT2CRs (38.8 ± 2.8%) and display the marker of neuronal activity c-FOS following lorcaserin treatment in mice. We next demonstrate, by knocking down expression of the GLP-1R within the NTS, that GLP-1R NTS neurons are necessary for 5-HT2CR dependent hypophagia. 1–4 hour cumulative food intake was significantly decreased in control mice but not GLP-1R knockdown mice following NTS 5-HT2CR activation (F(2,13) = 10.22, p = 0.002). We next established that PPGNTS neurons are also partly required for the anorectic effect of MC4R agonist melanotan-II (MT-II). MTII reduced cumulative food intake in both PPGNTS neuron ablated and control mice at 1–4 hours (treatment F(1,11) = 107.5, p<0.0001). However, PPGNTS neuron ablated mice were resistant to the anorectic effect of MTII 21 hours (treatment F(1,11) = 4.733, p = 0.052).

These data provide insight into the therapeutic mechanisms of obesity mediations and reveal key brain circuits modulating feeding.

Nutrition in the treatment, management and prevention of disease: nutrition strategies for disease prevention, nutrition in the management and treatment.

Acknowledgments

This work was supported by the BBSRC (BB/R01857X/1 and BB/N017838/1).

References

D'Agostino, G, Lyons, D, Cristiano, C et al. (2018) Cell Metabolism 28(4), 533–534.10.1016/j.cmet.2018.07.017CrossRefGoogle Scholar
Alhadeff, AL, Mergler, BD, Zimmer, DJ et al. (2017) Neuropsychopharmacology 42, 1471–1479.CrossRefGoogle Scholar
Holt, MK, Richards, JE, Cook, DR et al. (2019) Diabetes 68(1), 21–33.CrossRefGoogle Scholar